ArticleJournal of hematology & oncology2023

Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease.

Jonas S Heitmann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.